MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

BioMarin Pharmaceutical Inc

Fechado

SetorSaúde

54.57 -0.26

Visão Geral

Variação de preço das ações

24h

Atual

Mín

53.99

Máximo

55.18

Indicadores-chave

By Trading Economics

Rendimento

241M

426M

Vendas

80M

825M

P/E

Médio do Setor

15.935

35.739

EPS

1.44

Margem de lucro

51.637

Funcionários

3,040

EBITDA

95M

319M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+77.7% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.2B

10B

Abertura anterior

54.83

Fecho anterior

54.57

Sentimento de Notícias

By Acuity

20%

80%

42 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2025, 16:58 UTC

Ganhos

BMW Trims 2025 View, Citing Weaker Performance in China

7 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 de out. de 2025, 23:19 UTC

Conversa de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 de out. de 2025, 22:40 UTC

Conversa de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 20:44 UTC

Ações em Alta

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 de out. de 2025, 19:42 UTC

Conversa de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 de out. de 2025, 19:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 de out. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 de out. de 2025, 15:33 UTC

Conversa de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 de out. de 2025, 15:25 UTC

Conversa de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 de out. de 2025, 15:15 UTC

Conversa de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 de out. de 2025, 14:52 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparação entre Pares

Variação de preço

BioMarin Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

77.7% parte superior

Previsão para 12 meses

Média 97.2 USD  77.7%

Máximo 122 USD

Mínimo 60 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para BioMarin Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

18

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

59.405 / 62.19Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

42 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat